Dashboard
Manage Tickers

MOR


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

morpheus-launches-20-million-in-rewards-for-ai-compute-providers
Morpheus Launches $20 Million In Rewards F...
12/11/2024 15:15:10

Morpheus, a decentralized platform for deploying AI-driven “Smart Agents,” has launched a $20 million reward program for comput...

morphosys-announces-voluntary-delisting-from-the-nasdaq-global-market-expects-that-the-last-trading-day-will-be-on-or-about-august-2-2024
MorphoSys Announces Voluntary Delisting Fr...
07/12/2024 22:11:35

MorphoSys AG ((FSE: MOR, NASDAQ:MOR) today announced that it has formally notified the Nasdaq Stock Market of its intention to ...

novartis-to-squeeze-out-morphosys-minority-shareholders-initiate-delisting
Novartis to Squeeze Out MorphoSys Minority...
06/20/2024 07:13:04

MorphoSys AG ((FSE: MOR, NASDAQ:MOR) today announced that the company has entered into a delisting agreement with Novartis BidC...

12-health-care-stocks-moving-in-mondays-after-market-session
12 Health Care Stocks Moving In Monday's A...
05/27/2024 20:31:32

Core News & Articles
Novartis Meets All Tender Offer Conditions...
05/16/2024 09:46:16

Novartis secured 79.6 percent acceptance by MorphoSys shareholders during the initial acceptance period, reaching the minimum 6...

morphosys-group-ag-anticipates-close-of-proposed-acquisition-by-novartis-in-h1-2024-submit-a-new-drug-application-for-pelabresib-in-combination-with-ruxolitinib-in-myelofibrosis-to-fda-and-marketing-authorization-application-to-european-medicines-agency-in-h2-2024
Morphosys Group Ag Anticipates Close Of Pr...
04/29/2024 20:22:45

morphosys-group-ag-q1-2024-eps-927-down-from-094-yoy-revenue-275m-up-from-243m-yoy
MorphoSys Group AG Q1 2024 EPS €(9.27) Dow...
04/29/2024 20:14:22

morphosys-says-novartis-deal-progressing-steadily-despite-safety-concerns-over-bone-marrow-cancer-drug-pelabresib
MorphoSys Says Novartis Deal Progressing S...
04/29/2024 16:36:10

MorphoSys faces safety concerns over pelabresib, a myelofibrosis treatment. Physicians report patients transitioning rapidly to...

incyte-should-consider-significant-stock-buyback-and-prioritize-rd-analyst-recommends
Incyte Should Consider Significant Stock B...
04/23/2024 19:03:10

Incyte acquires Escient Pharmaceuticals for $750 million, bolstering its pipeline. Cantor Fitzgerald initiates coverage with a ...

Core News & Articles
MorphoSys AG Form SC TO-T/Amended Shows No...
04/15/2024 19:55:01

On 11 April 2024, Novartis BidCo, Basel, Switzerland, ("Bidder") has published the offer document regarding its takeove...

morphosys-management-board-and-supervisory-board-recommend-shareholders-accept-public-takeover-offer-by-novartis-for-6800-per-share-in-cash
MorphoSys' Management Board And Supervisor...
04/11/2024 13:09:37

Novartis offers € 68.00 per share in cash, representing a total equity value of € 2.7 billionShareholders benefit from attracti...

Core News & Articles
Novartis Tender Offer For Morphosys Comme...
04/11/2024 08:52:50

Novartis published today the offer document for the voluntary public takeover offer by its wholly owned subsidiary Novartis Bid...

morphosys-bags-us-antitrust-clearance-of-proposed-acquisition-by-novartis-under-hsr-act
MorphoSys Bags US Antitrust Clearance of P...
03/22/2024 07:04:21

MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced the receipt of U.S. antitrust clearance under the Hart-Scott-Rodino Antitrus...

wells-fargo-downgrades-morphosys-to-equal-weight-raises-price-target-to-1825
Wells Fargo Downgrades MorphoSys to Equal-...
03/14/2024 20:07:04

Wells Fargo analyst Derek Archila downgrades MorphoSys (NASDAQ:MOR) from Overweight to Equal-Weight and raises the price tar...

morphosys-q4-earnings-insights
MorphoSys: Q4 Earnings Insights
03/13/2024 20:20:23

morphosys-q4-eps-033-beats-009-estimate-sales-6351m-miss-6789m-estimate
MorphoSys Q4 EPS $0.33 Beats $0.09 Estimat...
03/13/2024 20:16:26

MorphoSys (NASDAQ:MOR) reported quarterly earnings of $0.33 per share which beat the analyst consensus estimate of $0.09 by 266...

earnings-scheduled-for-march-13-2024
Earnings Scheduled For March 13, 2024
03/13/2024 10:15:56

Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share...

earnings-outlook-for-morphosys
Earnings Outlook For MorphoSys
03/12/2024 15:02:28

Core News & Articles
MorphoSys Spokesperson Says "This Story Is...
02/06/2024 18:49:01

Why Novartis is going to walk from its acquisition of MorphoSys (statnews.com) Novartis said Monday that it intends to buy Morp...

novartis-agrees-to-acquire-german-blood-cancer-drug-developer-morphosys-for-27b
Novartis Agrees To Acquire German Blood Ca...
02/06/2024 13:46:05

Novartis' €2.7 billion public takeover offer for MorphoSys, unlocking a promising oncology pipeline with pelabresib and tul...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION